Pozen

Pharma

How arthritis drug Vimovo could ease Pozen’s PA32540 regulatory pain

Osteoarthritis drug Vimovo‘s sales disappointed early and its U.S. prescriptions have declined as of late, but for all of those commercialization pains, the drug has become an unexpected regulatory beacon for Pozen‘s (NASDAQ:POZN) latest drug candidate. PA32540 is Pozen’s safer aspirin, a compound drug that the Chapel Hill, North Carolina company developed for secondary prevention […]

Pharma

Safer aspirin is strong in phase 3; Pozen plans 3Q NDA filing

The delayed-release aspirin compound that Pozen (NASDAQ:POZN) has developed to protect against cardiovascular disease showed in clinical trials that it causes fewer ulcers compared to aspirin alone. With those positive phase 3 clinical trial results in hand, Pozen now expects to file a new drug application on PA32540 in the third quarter. John Plachetka, CEO […]

Pharma

How arthritis drug Vimovo shaped POZN’s strategy on its heart drug

Arthritis represents a large medical need but it is served by several products that carry gastrointestinal risks. Arthritis treatment Vimovo, developed as an alternative that’s easier on the stomach, was intended to address that need. Backed by the marketing muscle of pharma giant AstraZeneca (NYSE:AZN), Pozen (NASDAQ:POZN), which developed the drug, had every expectation it […]

Pharma

Pozen strikes manufacturing pact with Patheon for heart drug

The new cardiovascular drug being developed by Pozen (NASDAQ:POZN) does not yet even have a name, but it now has a manufacturer to produce it once it secures U.S. Food and Drug Administration approval. The Chapel Hill, North Carolina pharmaceutical company has reached a supply agreement with contract drug manufacturer Patheon (TSX:PTI), according to securities […]

Pharma

Arthritis drug Vimovo’s slow sales are a pain to Pozen

If you only looked at  Pozen‘s (NASDAQ:POZN) top and bottom lines from its third-quarter earnings, you might have missed a key detail affecting the pharmaceutical company’s financial performance. Although Chapel Hill, North Carolina-based Pozen’s revenue grew and its loss narrowed in the third quarter, the company insists results should be better and management pins those […]

Pharma

Change of heart: Why Pozen now wants to partner its cardiovascular drug

Digital drug marketing has been pharmaceutical company Pozen‘s (NASDAQ:POZN) mantra for much of this year. The Chapel Hill, North Carolina-based company has made clear that when it goes to market with its new cardiovascular drug, a digital strategy will dictate its reach to patients and physicians in ways that traditional pharmaceutical sales representatives have not […]

Pharma

Pozen’s digital drug marketing plan: A prescription for the pharma industry?

The digital communication consumers favor today to discuss retail products and food might have more to say about the future of pharmaceutical marketing than the still-ubiquitous television commercials promoting the latest lifestyle drugs. Pozen (NASDAQ:POZN), a Chapel Hill, North Carolina drug-development company, took the unusual step in July of appointing a digital advisory board whose […]

Pharma

Generic drugs firms appeal patent ruling on Pozen migraine drug

Pozen‘s (NASDAQ:POZN) patent fight to protect its migraine headache drug Treximet is not yet over. The Chapel Hill, North Carolina-based pharmaceutical company won a patent litigation court victory last month when a federal judge in Texas ruled that Pozen’s drug patents for Treximet were valid and enforceable. But Pozen disclosed in securities filings that generic […]